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While no consistent effect was obtained in regard to the degreeP2 receptor antagonist PPADS inhibits mesangial cell prolifera-
of mesangiolysis, influx of inflammatory cells, proteinuria ortion in experimental mesangial proliferative glomerulonephritis.
blood pressure, PPADS treatment increased serum creatinineBackground. Although extracellular nucleotides have been
and urea in anti-Thy1 rats. P2Y receptor expression (P2Y2 andshown to confer mitogenic effects in cultured rat mesangial cells
P2Y6) was detected in cultured MC and isolated glomeruli,through activation of purinergic P2 receptors (P2Y receptors),
and demonstrated a transient marked increase during anti-thus far the in vivo relevance of these findings is unclear. Virtu-
Thy1 disease.ally all cells and in particular the dense granules of platelets
Conclusion. These data strongly suggest an in vivo role forcontain high levels of nucleotides that are released upon cell
extracellular nucleotides in mediating early MC proliferationinjury or platelet aggregation. In experimental mesangial pro-
after MC injury.liferative glomerulonephritis in the rat (anti-Thy1 model), mes-
angiolysis and glomerular platelet aggregation are followed
by a pronounced mesangial cell (MC) proliferative response
leading to glomerular hypercellularity. Therefore, we exam- Mesangial proliferative glomerulonephritis, character-ined the role of extracellular nucleotides and their correspond-
ized by excessive mesangial cell (MC) proliferation, acti-ing receptors in nucleotide-stimulated cultured mesangial cells
vation, and matrix expansion, is the most common typeand in inflammatory glomerular disease using the P2 receptor
antagonist PPADS. of glomerulonephritis in the Western world [1]. Mesan-
Methods. The effects of PPADS on nucleotide- or fetal calf gial proliferative glomerulonephritis progresses to end-
serum (FCS)-stimulated proliferation of cultured MC were stage renal failure in more than 25% of all patients. Inmeasured by cell counting and [3H]thymidine incorporation
contrast to postinfectious proliferative glomerulonephri-assay. After induction of the anti-Thy1 model, rats received
tis, spontaneous resolution of the disease is uncommoninjections of the P2-receptor antagonist PPADS at different
doses (15, 30, 60 mg/kg BW). Proliferating mesangial and non- and effective therapy is unknown. The mechanisms of
mesangial cells, mesangial cell activation, matrix accumulation, how MC injury can lead to excessive MC proliferation
influx of inflammatory cells, mesangiolysis, microaneurysm for- are still incompletely understood, but are of essentialmation, and renal functional parameters were assessed during
importance for developing effective treatment for prolif-anti-Thy1 disease. P2Y-mRNA and protein expression was
erative glomerulonephritis.assessed using RT-PCR and real time PCR, Northern blot
analysis, in situ hybridization, and immunohistochemistry. In the anti-Thy1 model of mesangial proliferative glo-
Results. In cultured mesangial cells, PPADS inhibited nucle- merulonephritis in the rat [2–4], a single injection of anti-
otide, but not FCS-stimulated proliferation in a dose-depen- thymocyte antibody results in an acute, complement-dent manner. In the anti-Thy1 model, PPADS specifically and
dependent MC injury (days 0 to 2) with proteinuria,dose-dependently reduced early (day 3), but not late (day 8),
followed by a MC proliferative response that is accompa-glomerular mesangial cell proliferation as well as phenotypic
activation of the mesangium and slightly matrix expansion. nied by overproduction of extracellular matrix proteins
(days 3 to 10) [5]. In contrast to human mesangial prolif-
erative diseases, the pathological glomerular changes areKey words: purinergic P2 receptors, cell growth, extracellular nucleo-
completely reversible. Despite dramatic MC injury andtides, platelet aggregation, anti-Thy disease, injury, matrix expansion,
glomerular hypercellularity. subsequent proliferation during the time course of this
experimental disease, the glomeruli resume normal mor-Received for publication July 7, 2000
phology within several weeks. Recently, our group hasand in revised form May 1, 2002
Accepted for publication June 17, 2002 demonstrated that after MC injury in this model, the
few remaining hilar and extraglomerular MC migrate 2002 by the International Society of Nephrology
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and proliferate to the glomerular periphery in a coordi- strated in cultured MC, where PPADS dose dependently
inhibited nucleotide, but not FCS-induced MC prolifera-nated fashion perfectly restoring the glomerular architec-
ture [6]. This fascinating healing capacity of an injured tion. In addition, PPADS dose-dependently inhibited MC
proliferation in vivo in the anti-Thy1 model. Consistentglomerulus suggests a feedback mechanism and cross talk
between injured/dying cells and the remaining neighbor- with the release and paracrine action of nucleotides dur-
ing the mesangiolytic phase, PPADS was predominantlying cells resulting in restitution and integrity.
Potential candidates initiating the repair process after effective in decreasing the early MC proliferative re-
sponse in this model. MC phenotypic activation and toinjury are cytoplasmic factors such as nucleotides. While
recent studies have demonstrated that extracellular nu- a slight extent matrix expansion were decreased by
PPADS treatment. No consistent significant effect wascleotides stimulate growth of cultured MC [7, 8], the in
vivo relevance of this finding is unknown. Nevertheless, obtained in regard to the degree of mesangiolysis, influx
of inflammatory cells, proteinuria or blood pressure,the cytosol of virtually all cells contains nucleotides in
high concentrations (millimolar range) [9], from where while serum creatinine and urea were increased by the
PPADS treatment. Furthermore, P2Y2 and P2Y6 recep-they can be released into the extracellular space upon
damage. Nucleotides also are released from aggregated tor expression was detected in cultured MC and in-
creased in glomeruli during the time course of anti-Thy1platelets in which they are stored in the dense granules
[9, 10]. Therefore, in the initial phase of glomerular in- disease, suggesting that extracellular nucleotides act po-
tentially via these receptors. These data strongly suggestflammatory disease when cell damage or cell lysis (for
example, mesangiolysis), platelet aggregation, and influx an in vivo role for extracellular nucleotides in mediating
early MC proliferation after MC injury.of inflammatory cells is maximal, high amounts of locally
released nucleotides may participate in the induction of
MC proliferation in a paracrine fashion as part of a
METHODS
coordinated repair process. On the other hand if cell
Materialsinjury continues, the same mechanism may cause a vicious
cycle leading to an exaggerated proliferative response such Dulbecco‘s modified Eagle’s medium (DMEM) was
purchased from Biochrom (Berlin, Germany), fetal calfas in mesangial proliferative glomerulonephritis.
Extracellular nucleotides are ligands of cell surface serum (FCS) from Boehringer (Mannheim, Germany),
bovine insulin from Sigma (Deisenhofen, Germany) andproteins that are designated P2 receptors [11]. P2 recep-
tors are devided into two major families, the ATP-gated [3H]thymidine from Amersham Buchler (Braunschweig,
Germany). The nucleotides ATP (free of pyrogens),ion channels (P2X receptors) and the G-protein coupled
P2Y receptors [12]. Regarding the different members of adenosine-5-O-(3-thio)triphosphate (ATPS) were from
Boehringer; UTP and UDP were from Sigma.these families, the P2Y1 receptor can be activated by
adenine nucleotides [13], the P2Y2 equipotently by aden- Pyridoxalphosphate-6-azophenyl-2,4,-disulfonic acid
(PPADS) was synthesized in the laboratory of Prof. Dr.osine 5-triphosphate (ATP) and uridine 5-triphosphate
(UTP) [14], as can the P2Y4 receptor (at least concerning Lambrecht, Frankfurt, Germany [24].
rat tissues) [15], the P2Y6 is selectively activated by UDP
Mesangial cell culture[16], and the P2Y11 receptor by ATP [17]. The character-
ization of the diverse P2 receptors has been impeded To determine if the P2-receptor antagonist PPADS
specifically inhibits nucleotide-induced MC proliferationbecause of the lack of subtype-selective antagonists. In
addition, characterization is potentially problematic if in vitro, rat MC from passage 20 to 30 were prepared,
characterized and maintained as described previouslysolely based on a pharmacological agonist approach due
to enzymatic degradation and interconversion of extra- [7]. For determination of MC proliferation, growth ar-
rested (0.5% FCS) cultured MC were either stimulatedcellular nucleotides [18], the autocatalytic release of ATP
and UTP [19, 20], and the coexpression of multiple P2 with extracellular nucleotides or with 10% FCS and both,
rate of DNA synthesis and cell number were determinedreceptors [21]. Combined molecular and pharmacologi-
cal studies circumvent, at least in part, these difficulties. versus controls (PBS). All cell culture experiments were
done in triplicate.Studies also suggest that P2Y receptor activation induces
mitogenic effects in vitro [7, 22].
Cell proliferation assaysThe present study investigated if locally released extra-
cellular nucleotides participate in the mesangial mito- DNA synthesis was measured by incorporation of
[3H]thymidine into cellular DNA as described [25]. MCgenic response after MC injury in experimental mesan-
gial proliferative glomerulonephritis (anti-Thy1 model) were seeded in 96-well microtiterplates in a density of
5  103 cells/mL in DMEM containing 10% FCS. Afterin vivo by administration of the P2 receptor-specific in-
hibitor, pyridoxalphosphate-6-azophenyl-2,4,-disulfonic attachment of the cells overnight they were washed three
times with phosphate-buffered saline (PBS) and kept inacid (PPADS) [11, 23]. Specificity of PPADS was demon-
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resting medium (DMEM with 0.5% FCS) for a further volume was 200 L/100 g BW. In addition, six non-
three days. Thereafter, the MC were stimulated with manipulated animals were studied as normal controls.
extracellular nucleotides or 10% FCS in four- to sixfold Renal biopsies, as described previously, were performed
replicates. Control cells received an appropriate volume on days 3 and 5 [26]. On day 8 after disease induction
of PBS (serum starved cells). PPADS was added 20 min- the rats were sacrificed. Proteinuria was determined on
utes before stimulation with extracellular nucleotides. days 2/3, 4/5 and 7/8.
DNA synthesis was measured by a 24-hour pulse of To confirm the results of the first experiment and to
[3H]thymidine (1 Ci/mL) from 24 to 48 hours after determine whether increasing the dose still could en-
stimulation. At the end of the labeling period the cells hance the effects of PPADS treatment, a second experi-
were washed twice with PBS, trypsinized, and harvested ment with 12 anti-Thy1 diseased rats was performed (Fig.
onto cellulose filters with an automated cell harvester 1B). Six rats each either received normal saline (group
(Cambridge Technology, Watertown, MA, USA). Fi- D) or 60 mg PPADS/100 g BW (group E) every 12 hours
nally, the radioactivity retained on the filter was meas- (half the dose IV and half the dose IP). Renal biopsies
ered in a LKB rack szintillation -counter. were performed at seven hours and two days after dis-
For determination of the cell number MC were seeded ease induction. Sacrificial biopsies were obtained on day
into 24-well plates at a density of 18  103 cells/well. 3. A 24-hour urine collection for protein measurement
After cell attachment overnight the cells were growth and serum for creatinine and urea was collected on days
arrested for three days in resting medium and stimulated 2/3. To examine hemodynamic changes by PPADS treat-
with extracellular nucleotides. PPADS was added 20 ment, blood pressure measurements were performed by
minutes before the stimulation. After 72 hours, the MC tail plethysmography before and twice after disease in-
were trypsinized and counted in an automated cell duction.
counter (Coulter Electronics, Luton, Beds, UK). In renal biopsies the total cell number and number
To exclude effects on cell toxicity, Trypan blue exclu- of proliferating cells [as defined by immunostaining for
sion was performed at each concentration of nucleotides. proliferating cell nuclear antigen (PCNA)], number of
proliferating MC (by double immunostaining for PCNAAnimal model and experimental protocol
and the anti-Thy1 antigen), number of infiltrating mono-
Forty male Sprague-Dawley rats (Charles River, Sulz- cytes/macrophages (ED-1) and platelets (PL-1), MC
feld, Germany) weighing 160 to 200 g at the beginning phenotypic change (-smooth muscle actin expression
of the experiment were studied. The animals were fed by MC) as well as matrix expansion (type I and type IV
standard rat chow (Altromin 1324; Spezialfutterwerke collagen) were determined. The time course of glomeru-
GmbH, Lage, Germany) and tap water ad libitum.
lar P2Y2 and P2Y6 expression in the anti-Thy1 model wasAn anti-Thy1 disease model [2, 3] using a dose of 0.3
examined by Northern blot analysis, in situ hybridizationmL/100 g of a monoclonal anti-Thy1.1 antibody derived
and immunohistochemistry.from the hybridoma cell line OX-7 was established after
a dose-response study. It was characterized by severe Renal morphology and immunohistochemistry
mesangiolysis, platelet aggregation and pronounced glo-
Renal biopsies were fixed in methyl Carnoy’s solution,merular proliferation. In this animal model, complete
embedded in paraffin and cut into 5 m sections foranti-Thy1 antibody binding occurs within the first hour
indirect immunoperoxidase staining as described else-[26, 27]. To avoid potential interference of the P2 recep-
where [6]. Sections also were stained with the periodictor antagonist PPADS with anti-Thy1 antibody binding
acid Schiff (PAS) reagent and counterstained with hema-and subsequent disease induction, the first PPADS injec-
toxylin. For each biopsy, 40 to 70 cortical glomerulartion was administered 60 minutes after disease induction.
cross-sections containing more than 20 discrete capillaryThe first PPADS injection as a loading dose always con-
segments each were evaluated in a blinded fashion intained double the amount of PPADS compared to the
regard to the following parameters: total number of nu-following injections.
clei (per glomerular cross-section), degree of mesangio-The experimental design is outlined in Figure 1. After
lysis, and relative frequency of microaneurysms (per-the induction of the anti-Thy1 nephritis, rats were ran-
centage). Mesangiolysis was graded semiquantitativelydomly devided into three groups of four animals. Group
using the following scale: 0  no mesangiolysis; I B received PPADS injections of 15 mg/100 g body weight
segmental and focal mesangiolysis (25% of the glomer-(BW), group C of 30 mg/100 g BW, while group A re-
uli show partial dissolution of the mesangium); II  25ceived an equivalent volume of normal saline. The injec-
to 50% of the glomeruli are affected; III  most (50 totions were repeated every 12 hours and were adminis-
75%) glomeruli show severe mesangiolysis; and IV tered intravenously by group A and group B, while group
global mesangiolysis, where virtually all glomeruli showC received intravenous (IV; 15 mg/100 g) as well as
intraperitoneal (IP; 15 mg/100 g) injections. The injection a complete dissolution of the mesangial areas.
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Fig. 1. Schematic outline of the experimental
design. Detailed information is in the Methods
section.
For immunohistochemistry the following primary anti- ular cross section was determined and mean values per
biopsy were calculated [31]. The evaluation of the immu-bodies were included:
• 19A2 (Camon, Wiesbaden, Germany), a murine noperoxidase stains for -smooth muscle actin, collagen
type I and IV, and PL-1 were graded semiquantitativelyIgG monoclonal antibody against the proliferating cell
nuclear antigen (PCNA), which is expressed by activa- [32] and the mean score per biopsy was calculated. The
scores reflect mainly changes in the extent of the stainedtively proliverating cells [28].
• ED-1 (Serotec Ltd., Kidlington, Oxford, UK), a mu- area than the intensity of the staining: 0  very weak or
absent staining; 1	  weak staining with less than 25%rine monoclonal IgG1 to a cytoplasmic antigen present
in monocytes, macrophages, and dendritic cells. of the glomerular tuft showing focally increased staining;
2	  25 to 49% of the glomerular tuft with focally in-• PL-1, a murine monoclonal antibody against rat
platelets (a gift from W.W. Bakker, Groningen, Nether- creased staining; 3	  50 to 75% of the glomerular tuft
demonstrating increased staining; 4	  more than 75%lands) [29].
• 1A4 (Dako, Glostrup, Denmark), a murine mono- of the glomerular tuft stains strongly. It was previously
shown that this scoring system is reproducible betweenclonal IgG2A against smooth muscle -actin.
• OX-7 (Serotec), a murine monoclonal IgG1 anti- different observers. The data are in very good agreement
with that obtained by computerized morphometry [32].body against the Thy1 antigen, specific for MC.
• P2Y2-receptor, a rabbit polyclonal antibody (a gift The evaluation of the immunoperoxidase stain for the
P2Y2 purinoceptor was done using the MetaVue Imagingfrom B.K. Kishore, Cincinnati, Ohio, USA) [30].
• A rabbit polyclonal antibody to collagen I (Biogene- System (Visitron Systems, Puchheim, Germany) counting
the percentage of the positive area within the glomerulus.sis, UK).
• A goat polyclonal antibody to collagen IV (anti-
Immunhistochemical double staininghuman/bovine; Southern Biotechnology Associates, Inc.,
Birmingham, UK). To determine the number of proliferating MC, double
immunostaining for OX-7, a specific MC marker, and
PCNA was performed as described previously [6].Negative controls consisted of substitution of the pri-
mary antibody with an equivalent concentration of an
RNA preparation and Northern blot analysisirrelevant murine monoclonal antibody. For each biopsy,
30 to 60 cortical glomerular cross sections containing more For total RNA preparation from cultured MC or iso-
lated glomeruli the guanidinium thiocyanate/phenol/than 20 discrete capillary segments were evaluated in a
blinded fashion. The number of proliferating (PCNA	) chloroform extraction method [33] was used. For total
RNA extraction from glomeruli, renal tissue was pooledcells, monocytes/macrophages and platelets per glomer-
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either from three healthy rats or from two rats per time samples were cycled 45 times at 94
C for 30 seconds and
65
C for 60 seconds and 72
C for 40 seconds. The originalpoint following anti-Thy1 induction. For each time point
at least six animals were used, so that three different cDNA content of each sample was compared with an-
other sample using the Ct technique [38] as describedRNA samples were available. Isolation of glomeruli and
Northern blot analysis were done as described in [34, 35]. by the formula Ao/Bo  (1 	 E)(Ct,A–Ct,B), where Ao is
the initial copy number of sample A, Bo of sample B, EThe blots were either hybridized with a 2.0 kb P2Y2
cDNA-fragment [36] or a 1.4 kb P2Y6 cDNA-fragment is the efficiency of amplification, Ct,A is the threshold
cycle of sample A, and Ct,B is the threshold cycle of[37]. The full-length cDNA-probes were kindly provided
Dr. Y. Takuwa (Tokyo, Japan). Control hybridizations sample B. In our experiments, the amplification efficiency
was 1, as all analyses were performed during the same run.were performed using a 700-bp fragment of rat glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) cDNA. Therefore, the cDNA content of sample A compared to
sample B was calculated by subtracting the mean Ct
RT-PCR analysis (done in triplicates) of sample A from the mean Ct of
sample B ( Ct). Copies of the individual transcriptsThe reverse transcription (RT) reaction was per-
formed with 1 g DNaseI-treated (RQ1-DNaseI, Pro- in sample A were defined as 2CT copies of transcripts
in sample B. The rat -actin gene (primers: 5-TCG GTGmega) total RNA with the GeneAmp RNA-PCR Kit
(Perkin Elmer) in a 20 L reaction volume according to TGG ATT GGT GGC TCT A-3 and 5-CTG CTT GCT
GAT CCA CAT CTG-3 served as housekeeping genesthe protocol of the manufacturer. Oligo(dT)16 were used
as RT-primers. Specific oligonucleotide PCR-primers to assess the overall cDNA content.
(synthesized by Eurocentec) were designed from the pre-
In situ hybridizationviously published sequences of the P2Y2 [36] and P2Y6
[37] receptors using Lasergene Molecular Biology Soft- Fluorescin isothiocyanate (FITC)-labeled HybriProbe
oligonucleotides and controls (bases 781-809 of the totalware (DNA-STAR, London, UK): P2Y2 receptor sense
primer 5-CAGCGTGAGAGGGACCCGAA-3(bp 522- sequence) directed to the rat P2Y2-receptor have been
designed and manufactured by BIOGNOSTIK (Go¨ttin-541), P2Y2 receptor antisense primer 5-TGAGGTCAA
GTGATCGGAAG-3 (bp 826-807), P2Y6 receptor sense gen, Germany). In situ hybridization of rat P2Y2-receptor
(Accession No.: L46865) mRNA was performed on para-primer 5-CTGCGTCTACCGTGAGGATTTC-3 (bp
51-72), P2Y6 receptor antisense primer 5-GGCGGG formaldehyde fixed paraffin embedded tissue sections
using a non-radioactive Hybriprobe kit purchased fromCCATGCGACAGTAG-3 (bp 652-633). The polymer-
ase chain reaction (PCR) reaction conditions were as BIOGNOSTIK. Bound oligonucleotides were detected
via DAB-staining following enhancing the signal by Envis-follows: an initial denaturation step for two minutes at
95
C, followed by 25 cycles of 95
C for one minute, an- ion System (Dako, Hamburg, Germany).
nealing for one minute, 72
C for two minutes, and a final
Statistical analysisextension step (72
C) for seven minutes. The annealing
temperatures were 58
C for the P2Y2 and 70
C for the All values are expressed as mean  SD. Statistical sig-
nificance (defined as P  0.05) was evaluated using theP2Y6-specific primers.
Both negative (in which cDNA was omitted) and posi- Student t test.
tive (with cDNA from tissues known to express the P2Y
receptor) control reactions were performed. To test for
RESULTS
DNA-contamination minus-RT enzyme controls were
In vitro studiesrun for each sample. PCR products were size separated
on 1% agarose gels and visualized with ethidium bro- The P2 receptor antagonist PPADS inhibits nucleotide-,
but not FCS-stimulated proliferation in cultured rat MC.mide staining.
Mesangial cell proliferation was measured by cell counts
Real-time quantitative RT-PCR and by [3H]thymidine incorporation as an estimate for
DNA synthesis. The thymidine uptake was determinedReal-time quantitative RT-PCR was performed on a
TaqMan ABI 7000 Sequence Detection System using at the end of a 24-hour labeling period 48 hours after
stimulation of resting MC as described in methods. OneSybrGreen PCR mastermix (PE Biosystems, Weiter-
stadt, Germany) and primers from MWG AG Biotech representative experiment (out of three) is demonstrated
in Figure 2.(Ebersberg, Germany): rat P2Y2 receptor sense: 5-GAG
GGA CCC GAA TCA CCT GC-3; rat P2Y2 receptor anti- As shown in Figure 2, stimulation of MC with 300
mol/L UTP, 300 mol/L UDP or with 100 mol/Lsense: 5-TCG GGC CAT GAG CAC GTA AC-3; rat
P2Y6 sense: 5-CCG CCG GAC CCT GAC CCG TT-3; ATPS significantly increased the cell counts by 19.8%,
46.9%, and 24.0%, respectively, as well as the [3H]thymi-rat P2Y6 antisense: 5-TAC CAC CCA AGC AGC ACG
GC-3. After an initial hold of three minutes at 94
C the dine uptake compared to control cells treated with PBS.
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Fig. 2. PPADS dose-dependently inhibits nu-
cleotide-stimulated proliferation in cultured
rat mesangial cells (MC). Resting MC were
stimulated with 300 mol/L UTP, 300 mol/L
UDP or 100 mol/L ATPS, respectively.
Twenty minutes before stimulation, MCs were
pretreated with different concentrations of
PPADS as indicated. Seventy-two hours after
stimulation, cells were harvested and cell counts
determined. Effect of PPADS on cells counts
of UTP and UDP stimulated MC (A), of
ATPS stimulated MC (B) and on resting MC
(C ). For DNA-synthesis [3H]thymidine incor-
poration was measured (24-hour labeling pe-
riod from 24 to 48 hours) after stimulation with
extracellular nucleotides as described in the
Methods section. Effect of PPADS on the
DNA-synthesis of nucleotide-stimulated (D)
and FCS-stimulated MC (E). MCs only treated
with PBS are termed Co. P  0.05 versus
nucleotide-stimulated MCs without PPADS
pretreatment.
Incubation with the P2 receptor antagonist PPADS 20 expected from pharmacological data [7, 8]. Additionally,
the mRNA transcripts of the P2Y6 receptor was found inminutes prior to stimulating resting MC caused a signifi-
cant decrease of the extracellular nucleotide-mediated cultured MC. Using RT-PCR, the amplification products
were single bands that corresponded to the predictedproliferation as assessed by cell counts. The nucleotide-
antagonizing effect of PPADS was concentration-depen- sizes of the target sequences. Northern blot analysis re-
vealed transcripts of about 3.0 kb and 2.2 kb of the P2Y2dent. PPADS in the 10 to 30 mol/L range completely
abolished the mitogenic effect of 300 mol/L UTP, and and P2Y6 receptor. Both P2Y mRNA transcripts also
were found in total RNA preparations of whole kidneypartially inhibited the proliferative effect of 300 mol/L
UDP or 100 mol/L ATPS without causing significant and isolated glomeruli from healthy rats. The sizes of
the Northern blot signals of the P2Y2 and P2Y6 receptorcytotoxic effects as evaluated by Trypan blue exclusion.
Comparable data were obtained using [3H]thymidine in- are comparable to the transcripts described in the litera-
ture [35–37].corporation as a measure of MC proliferation as shown
in Figure 2D. In contrast, PPADS did not inhibit prolifer-
In vivo studiesation of either serum-deprived control MC or MC stimu-
lated with 10% FCS (Fig. 2 C, E). PPADS treatment in experimental anti-Thy1 nephritis
reduces MC proliferation without affecting the prolifera-Cultured MC and isolated glomeruli express P2Y2 and
P2Y6 receptor mRNA. Using RT-PCR and Northern tive activity of glomerular non-mesangial cells. In control
rats (group A), which did not receive PPADS, the pro-blot analysis the mRNA expression of the P2Y2 and P2Y6
receptors in cultured MC was examined. Figure 3 shows gression of anti-Thy1 nephritis followed the typical dis-
ease course as previously reported [4–6, 27, 39]. Asthat MC express the mRNA of the P2Y2 receptor as
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Fig. 3. P2Y2 and P2Y6 receptor mRNA is ex-
pressed in cultured rat MC, kidney and iso-
lated glomeruli. (A) RT-PCR analysis was
performed with DNase I treated RNA from
proliferating MC, kidney (K), lung (L) and
isolated glomeruli (G). Reverse transkription
was performed with 1 g total RNA each,
followed by PCR amplification using primers
specific for the P2Y2 and P2Y6 receptor (Ta-
ble 1). Only RNA preparations that showed
no PCR products in minus-RT reactions were
used to exclude false positive signals as a result
of genomic DNA contamination. PCR prod-
ucts were electrophoresed on 1% agarose gels
and visualized with ethidium bromide stain-
ing. The sizes of the expected PCR fragments
are indicated on the right side. Results shown
are representative of 4 to 5 independent ampli-
fications. (B) Northern blot analysis, in which
20 g of total RNA were subjected to agarose
gel electrophoresis, transferred to nylon mem-
brane and hybridized with 32P-labeled specific
cDNAs as described in Methods. Control hy-
bridization was performed using glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH)
as a reference for gel loading. Results shown
are representative of 3 independent Northern
blot hybridizations. Signs represent: () rest-
ing MC; (	) proliferating MC (10% FCS).
depicted in Figure 4A during the first three days after on days 5 and 8 versus untreated rats (Fig. 4A). To
determine whether an additional dose increase woulddisease induction (due to mesangiolysis), total glomerular
further enhance the PPADS effect in anti-Thy1 disease,cell number significantly decreased compared to normal
a second experiment using a higher PPADS dose (60healthy rats, while a marked glomerular hypercellularity
mg/kg BW) focusing on the first three days of diseasehas already developed five days after disease induction.
(maximal effects) was performed. Comparable to the doseGlomerular cell proliferation as determined by PCNA
of 30 mg/kg BW (first experiment), the high PPADS dosestaining (a marker of DNA synthesis) was already in-
(60 mg/kg BW) decreased MC proliferation (PCNA	/creased on day 3, maximal on day 5 and ceased toward
OX-7	 cells) by 45% on day 3 (not shown).normal on day 8. Consistent with previous studies [4],
In contrast, in both experiments and independent ofmost of the proliferating glomerular cells during anti-
the dose of PPADS the number of proliferating non-Thy1 disease are MC, which are identified by PCNA and
MC was unchanged (Fig. 4) at any time point during theOX-7 (directed against the Thy1 marker of MC) staining
disease. Since microaneurysms are thought to develop as(Table 1 and Fig. 4 B-E) [6]. As demonstrated earlier,
a consequence of glomerular endothelial cell injury (pri-the proliferating non-MC are mainly of glomerular endo-
mary or secondary to mesangiolysis) [6, 35] and the lack
thelial origin and identified as PCNA positive/OX-7 neg-
of repair (proliferation of non-MC), we also investigated
ative cells (Fig. 4 B-E) [31]. whether microaneurysm formation is affected by PPADS.
As shown by double immunostaining in Figure 4, the As demonstrated in Table 1, microaneurysm formation
P2 receptor antagonist PPADS specifically decreased was not affected by PPADS treatment at any time point
MC proliferation (by PCNA/OX-7 staining) predomi- during disease.
nantly on day 3 by 43%/65% (15 mg/30 mg PPADS) and To control for differences in disease induction and
less pronounced on day 5 (by 27%/33%), but not on day mediation of the MC injury and death, mesangiolysis
8. The PPADS effect was significant at a dose of 30 mg was assessed by a semiquantitative scoring system and
PPADS/kg BW, but did not reach significance at the glomerular cell number also was counted. In the early
lower dose of 15 mg PPADS/kg BW. In addition, treat- phase of disease (day 2), mesangiolysis scores and glo-
ment with 30 mg PPADS/kg BW reduced total glomeru- merular cell counts were unchanged versus controls (Ta-
ble 1).lar cell number starting on day 3 with a maximal effect
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Fig. 4. PPADS inhibits glomerular MC proliferation without altering proliferation of non-MC in vivo in mesangial proliferative glomerulonephritis.
Group A consisted of rats with untreated anti-Thy1 nephritis, normal refers to healthy animals, while group B received 15 mg PPADS/kg BW
and group C 30 mg PPADS/kg BW. MC proliferation was determined by double immunostaining using an antibody to PCNA, a marker f DNA
synthesis, and an antibody to OX-7 that is specific for MC. Proliferating MC were identified as PCNA	/OX-7	 and proliferating non-MC as
PCNA	/OX-7. (A) Total glomerular cell number during anti-Thy1 disease (per glomerular cross section). P  0.05 versus control group A.
Quantification of proliferating MC and non-MC on day 3 (B), day 5 (C), and day 8 (D). (E) A representative biopsy at day 3 after disease in-
duction of an untreated anti-Thy1 rat (group A), where proliferating glomerular cells were identified by nuclear staining for PCNA in black and MC
by the cytoplasmic stain for the OX-7 antigen in brown. Examples of proliferating MC (black) and non-MC (white) are indicated with arrows.
The P2 receptor antagonist PPADS inhibits expression on glomerular cell proliferation, 30 mg/kg BW of PPADS
significantly inhibited MC phenotypic change on day 3of -smooth muscle-actin and matrix accumulation in
anti-Thy1 nephritis. Associated with the glomerular pro- and to a lesser extent on day 5 as measured by the
induction of -smooth muscle-actin by MC (Table 1). Onliferation is the de novo expression of -smooth muscle-
actin, which is considered to be a marker for MC activa- day 8 after disease induction no changes in MC activation
could be observed in any treatment group versus un-tion and phenotypic change during the time course of
mesangial proliferative nephritis. Similar to its effects treated controls.
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Table 1. Quantification of -smooth muscle actin, matrix expansion (collagen I and IV staining), macrophage (ED-1) and platelet (PL-1)
influx, glomerular mesangiolysis and microaneurysm formation, proteinuria, serum creatinine, serum urea and systolic blood pressure
Experiment 1 Experiment 2
Effects on Group Day 3 Day 5 Day 8 Group 7 Hours Day 2 Day 3
-smooth muscle actin (score 0–4) A 0.990.15 2.790.25 2.530.59 D ND ND ND
B 0.840.14 2.410.07 2.780.42 E ND ND ND
C 0.510.15b 2.230.21b 2.500.34
MC matrix expansion (collagen IV, score 0–4) A 1.740.11 2.920.07 3.320.28 D ND ND ND
B 1.530.25 2.900.10 3.280.30 E ND ND ND
C 1.400.07b 2.630.17b 3.090.17
MC matrix expansion (collagen I, score 0–4) A 0.060.06 2.320.56 2.430.47 D ND ND ND
B 0.170.10 2.710.53 2.460.82 E ND ND ND
C 0.100.05 3.000.30 3.180.25
Glomerular microaneurysm % A 14.514.0 6.833.5 ND D ND 10.68.9 5.52.0
B 22.619.7 5.934.8 ND E ND 4.022.4 9.34.9
C 12.84.5 8.966.6 ND
Mesangiolysis (score 0–4) A 2.420.30 ND ND D ND 3.090.38 2.840.42
B 2.730.77 ND ND E ND 3.040.42 2.930.15
C 2.460.15 ND ND
Macrophage influx (ED-1	 cells/glomerulus) A 2.111.11 ND ND D 6.722.16 3.911.24 2.710.71
B 1.480.20 ND ND E 4.281.14 2.540.65 2.150.76
C 1.140.62 ND ND
Platelet aggregation (PL-1, score 0–4) D 1.550.33 0 0
E 1.800.17 0 0
Proteinuria mg/24 h A ND 44.429.7 57.427.3 D ND ND 31.019.1
B ND 69.826.4 57.026.5 E ND ND 38.528.5
C ND 16.54.90 48.826.7
Serum urea mg/dL D 42.534.09
E 62.034.13b
Serum creatinine mg/dL D 0.340.03
E 0.420.03b
Systolic blood pressure mm Hga D 91.204.40 84.717.1 ND
E 91.1010.8 84.013.1 ND
ND means not done. Values are meanSD.
a The systolic blood pressure of normal healthy rats was 91.79.8
bP  0.05
In control rats the glomerular immunostaining for type Transcripts of the potentially mitogenic P2Y receptors
are up-regulated during anti-Thy1 nephritis. To deter-I and IV collagen followed the typical previously pub-
lished course [5]. In the anti-Thy1 model, mesangial in- mine the mRNA levels of the P2Y receptors found in
cultured MC as well as in glomeruli of healthy rats (Fig. 3),duction of collagen I typically started around days 2/3
and peaked between days 5 and 8 as seen in this study. total RNA was harvested from isolated glomeruli during
the course of anti-Thy1 nephritis at different time pointsCollagen IV was already expressed at a baseline level
in the normal glomerulus and was markedly deposited and Northern blot analysis as well as real-time PCR analy-
sis using specific cDNA probes/primers for the P2Y2-in the glomerulus starting on day 2 and peaking between
days 5 and 8. PPADS treatment at a dose of 30 mg/kg and P2Y6 receptor was performed. Nothern blot analysis
revealed a transient increase of P2Y2 and P2Y6 receptorBW did show a significant decrease in collagen IV depo-
sition on day 3, but the effect was relatively minor and mRNA during anti-Thy1 disease (not shown) that was
confirmed and quantified by real-time PCR methodologynot seen at later time points during the course of disease
(Table 1). No consistent and significant differences in col- (via comparison to the housekeeping gene rat -actin)
as shown in Figure 5. In situ hybridiziation for P2Y2lagen I expression by MC were obtained in the PPADS
treated groups (Table 1). mRNA demonstrated little glomerular expression in
normal healthy rats (Fig. 6E), but markedly increasedPPADS did not change glomerular monocyte/macro-
phage and platelet influx. The maximum of the glomeru- glomerular expression (peaking on day 3) during the
time course of anti-Thy1 disease (Fig. 6F).lar influx of monocytes/macrophages was found as early
as seven hours after disease induction and slowly de- Immunocytochemical localization and quantification
of P2Y2 purinoceptor in glomeruli during anti-Thy1 ne-creased thereafter, which is in agreement with published
data [4, 27]. Glomerular platelet accumulation also peaked phritis. To further localize the glomerular P2Y2 purino-
ceptor protein, we performed immunoperoxidase stain-early in disease (7 hours) and rapidly declined thereafter.
PPADS affected neither the influx of ED-1 positive mono- ing on paraffin sections using a specific P2Y2 antibody as
characterized by Kishore et al [30]. In normal glomeruli,cytes/macrophages nor of PL-1 positive platelets at any
time point or PPADS dose (Table 1). little P2Y2 receptor is expressed (Fig. 6 A, D). During
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To demonstrate effectiveness and specificity of PPADS
with regard to blocking nucleotide mediated MC prolif-
eration, increasing doses of PPADS were added to cul-
tured MC, and cell proliferation was determined by cell
counts and [3H] thymidine incorporation assays. PPADS
dose dependently and specifically inhibited nucleotide
stimulated MC proliferation. Using Northern blot analy-
sis and RT-PCR, transcripts of the potentially involved
P2Y2 and P2Y6 receptors were detected in cultured MC.
It is now widely accepted that extracellular nucleotides
function as signaling molecules in a wide range of physio-
logical and pathophysiological processes [11] includingFig. 5. Glomerular P2Y2 () and P2Y6 () receptor mRNA expression
is increased during mesangial proliferative glomerulonephritis in the cell proliferation. Nucleotides are mitogens for a variety
rat. Expression of P2Y2- and P2Y6-mRNA in isolated glomeruli from of cell types such as cultured mouse fibroblasts [40],anti-Thy1 nephritic rats on day 0 (controls), day 2, day 3, and day 5 as
endothelial cells [41], aortic smooth muscle cells [22] asquantified by Real-time PCR normalized to the overall cDNA content
by the housekeeping -actin gene. Results shown are 3 to 4 independent well as glomerular MC [7]. Huwiler and Pfeilschifter
experiments with different rats. described the ATP-dependent activation of the MAP
kinase in MC [42]. The MAP kinase cascade connects
extracellular signals with intracellular mediators regulat-
ing gene expression and cell growth processes [43]. Asanti-Thy1 nephritis, the P2Y2 receptor was transiently
previously demonstrated by our group, extracellularincreased during anti-Thy1 nephritis, being mainly local-
ATP induces the immediate early genes c-fos, c-jun andized at the hilar region on day 3 (Fig. 6 B, D) and distrib-
egr-1 in cultured MC [44, 45], which are thought to beuted in a typical mesangial pattern at the peak expression
involved in cell growth responses.on day 5 (Fig. 6 C, D), while on day 7 expression already
PPADS has been shown to block recombinant homo-started to cease (Fig. 6D).
meric P2X1, P2X2, P2X3, and P2X5, heteromeric P2X2/3Basic functional data. During the study animals did
and P2X1/5 (IC50  0.1 to 5 mol/L) as well as P2Y1not show any signs of clinical adverse effects. During the
receptors (pA around 6.0) with similar potencies, buttime course of the experimental anti-Thy1 nephritis the
is weak or ineffective as an antagonist (IC5010 mol/L)24-hour proteinuria was markedly increased compared
at homomeric P2X4, P2X6, and P2X7, heteromeric P2X4/6to normal rats. PPADS did not influence protein excre-
and P2Y2, P2Y4, P2Y6, and P2Y11 receptors from differenttion in nephritic rats as shown in the Table 1 at any
species [11, 23]. However, species-dependent differencesgiven time point studied during the course of the disease.
in the pharmacology of PPADS at P2 subtypes have toSerum creatinine and serum urea on day 3 was increased
be considered [11, 15, 23]. Being inactive at the rat P2Y4in PPADS-treated versus control rats (Table 1). Since
receptor, PPADS inhibits human P2Y4 receptor-medi-PPADS potentially affects hemodynamics, systolic blood
ated responses [15]. Unfortunately, there are no data pub-pressure was monitored also and was not altered by
lished regarding the P2-antagonistic potency of PPADSPPADS in this experiment (Table 1).
at rat P2Y2 and P2Y6 receptors. Transcripts of P2Y2 and
P2Y6 (this study) as well as of P2X7 and P2Y4 have been
DISCUSSION found in MC [46]. However, the functional contribution
of these P2 subtypes on the inhibitory effects of PPADSThe aim of the present study was to examine if extra-
cellular nucleotides participate via their corresponding remains a subject for future investigations. Our data fur-
ther support the concept that UDP stimulated P2Y6 re-P2 receptors in the initiation of MC proliferation in vitro
as well as in vivo, and whether the P2 receptor antagonist ceptor and most likely the P2Y2 receptor, which are equally
stimulated by ATP and UTP, are critical in nucleotide-PPADS is able to block nucleotide specific effects in
cultured MC and in experimental glomerulonephritis. mediated MC mitogenicity. The strongest mitogenic ef-
fects in cultured MC were achieved with UDP, UTP andThus far, evidence that extracellular nucleotides confer
mitogenic signals in vivo is lacking. In the initial phase ATPS, which were at least partially reversible with
PPADS (Fig. 2). However, we cannot rule out the involve-of the anti-Thy1 model with glomerular cell damage and
platelet aggregation, nucleotides are released from the ment of other P2 receptor subtypes. For example, the
P2Y4 receptor displays the same agonist profile as doescytosol and the dense granules of platelets into the extra-
cellular space [7–10], which is followed by an excessive the P2Y2 receptor, at least concerning rat tissues [16],
and its mRNA is expressed in rat glomerular MC [46].MC proliferation being the hallmark of many glomerular
kidney diseases. Hence, the release of nucleotides and The most important finding in this study is that the P2
receptor antagonist PPADS inhibited the proliferationthe onset of MC proliferation coincide.
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Fig. 6. Glomerular localization of P2Y2 receptor protein (by immunohistochemistry) and mRNA (by in situ hybridization) during anti-Thy1
nephritis. Immunohistochemistry of P2Y2 protein (gray) in an healthy control rat demonstrates collecting duct (arrowhead) and faint glomerular
staining (A), which is markedly increased during mesangial cell proliferation in anti-Thy1 disease on day 3 (B) and day 5 (C ) in a typical mesangial
pattern. (D) Quantitation of the glomerular P2Y2 receptor protein during the time course of anti-Thy1 nephritis using computerized morphometry.
Increased glomerular P2Y2 receptor mRNA expression can also be demonstrated by in situ hybridization (gray) on day 5 (F ) versus healthy
control rats (E ).
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of glomerular MC in vivo. Administration of PPADS dur- early collagen IV expression was slightly reduced in
ing the course of experimental mesangial proliferative PPADS treated rats with anti-Thy1 disease.
glomerulonephritis leads to a significant reduction of glo- Depletion of monocytes/macrophages and/or platelets
merular proliferation. Double immunostaining for PCNA leads to a significant reduction in cell proliferation during
(proliferating cells) and OX-7 (MC) demonstrated that inflammatory processes as previously shown [4, 47]. To
this decrease of glomerular proliferation was due to spe- rule out that PPADS inhibits MC proliferation via reduc-
cific inhibition of MC proliferation. A PPADS dose of tion of infiltrating inflammatory cells and therefore a
30 mg/kg BW seemed to cause maximal blocking effects reduced release of nucleotides and/or cytokines, the glo-
compared to untreated controls, since a further twofold merular extent of macrophages and platelet infiltration
increase of the PPADS dose did not enhance this inhibi- also was determined. Nevertheless, neither influx of mac-
tory effect. On day 3 the proliferating MC were markedly rophages nor platelets was altered by the PPADS treat-
reduced by 65% compared to untreated controls. Inhibi- ment.
tion of the MC proliferation was followed by a significant The data presented here support the following concept
reduction of glomerular hypercellularity. Inhibition of of a role for nucleotides in mesangial cell injury and
MC proliferation by PPADS was restricted to the early proliferation: (1) Cytosolic prestored nucleotides are re-
phase of anti-Thy1 disease and was not compensated at leased into the extracellular space during the early phase
later time points. On day 8 of the anti-Thy1 model, an of anti-Thy1 disease, when maximal mesangiolysis and
equally low number of proliferating MC was detected platelet aggregation occur. (2) Extracellular nucleotides
in PPADS and untreated groups. In addition to its ex- trigger (or help to trigger) the remaining MC to prolifer-
pression in cultured MC, the potentially mitogenic P2 ate in a paracrine fashion. This may happen in coopera-
receptors P2Y2 and P2Y6 were expressed in glomerular tion with other factors such as cytokines as described in
isolates from normal rats and markedly increased during vitro [7, 37, 44, 45]. (3) In the context of a timely and
anti-Thy1 disease, as could be shown by Northern blot locally restricted cell injury such as the reversible anti-
analysis and quantitative Real-time PCR, in situ hybrid- Thy1 model, the release of nucleotides upon cell death
ization (P2Y2) as well as by immunohistochemistry using may support paracrine repair and regeneration of the
a specific antibody for the P2Y2 receptor [39]. P2Y2 re- surrounding tissue. On the other hand, when cell injury
ceptor protein (by immunostaining) clearly demon- continues and nucleotides are repeatedly released, a
strated a typical tree-like mesangial pattern with weak chronic stimulation of MC proliferation could lead to
expression in the normal glomerulus and strong induc- the typical hypercellular lesions of chronic-progressive
tion during the MC proliferative phase of disease. Early
mesangial proliferative glomerulonephritis. Further stud-
inhibition of MC proliferation by PPADS was associated
ies are needed to examine whether PPADS is able towith significant impairment of kidney function, as indi-
inhibit the development of a chronic progressive lesioncated by serum creatinine and urea measurements on
caused by repeated MC injury.day 3. Whether this finding is related to the structural
changes regarding an impaired glomerular repopulation
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